All-oral 6-month regimen for drug-resistant TB
Treatments studied
Part of Infections clinical trials.
This trial tests a 6-month all-oral combination of four drugs (bedaquiline, delamanid, linezolid, and levofloxacin) for people with drug-resistant tuberculosis. It aims to see if this shorter, simpler regimen works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You have tuberculosis that is resistant to rifampin (or to both rifampin and isoniazid).
- You have not used bedaquiline, delamanid, linezolid, or levofloxacin for more than 4 weeks in the past.
- You have a positive sputum culture or smear for TB within the last month, and have not had effective treatment for it in that time.
- You must not have serious heart problems (like long QT, arrhythmia, or heart failure) or severe liver or kidney disease.
- You are not pregnant, HIV-positive, or allergic to the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This trial tests a new 6-month treatment for people with multidrug-resistant tuberculosis (MDR-TB). It aims to see if this shorter treatment works well and can be used in France, offering a quicker option for recovery.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests a very short treatment for active lung TB in people aged 65 and older. The goal is to see if a short course of medicines can effectively cure TB without side effects.
Hear when a new Treatment Duration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.